Mono Pharmacare Limited
₹8.90▲ +0.00 (+0.00%)
MONOPHARMA·NSE·Healthcare
Market Cap
15.73 Cr
PE Ratio
44.50
Volume
14,000
Day High - Low
8.90 - 8.90
52W High-Low
22.05 - 7.50
₹8.90▲ +0.00 (+0.00%)
Market Cap15.73 Cr
PE Ratio44.50
Volume14,000
Day High - Low8.90 - 8.90
52W High-Low22.05 - 7.50
Mono Pharmacare Limited (MONOPHARMA): company summary
The company's revenue has grown by 10.8% annually over the past three years and rose 22.2% in the latest quarter compared to the same quarter a year earlier.
Mono Pharmacare Limited (MONOPHARMA) is a micro-cap Healthcare company valued at ₹16 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Mono Pharmacare Limited last traded at ₹8.9, unchanged on the day.
- Recent developments
- 2026-09-07: The DocStoX score increased to 3.1, but the verdict remained 'avoid' as the company continues to report zero net profit despite revenue growth. 2026-07-16: The score was 1.3, reflecting concerns about the company's financial health and lack of profitability.
- Financial performance
- The company's revenue has grown by 10.8% annually over the past three years and rose 22.2% in the latest quarter compared to the same quarter a year earlier. However, net profit has collapsed, falling to ₹0 crore in the latest quarter and over the past three years, with a net profit margin of 0.0%. Return on equity and return on capital employed are low at 1.1% and 5.0%, respectively, indicating weak profitability and poor capital efficiency.
- Valuation multiples
- The stock trades at 44.5 times earnings, a premium to the Healthcare median of 32.0, 0.50 times book value.
- Things to watch
- The company has a balance-sheet safety score of 0.0, indicating severe financial risk. It is not paying dividends despite reporting profits, and the low interest coverage ratio suggests it may struggle to meet debt obligations. The net profit has dropped to zero, and the company is capitalizing interest costs, which could distort financial results.
- Where it stands
- The DocStoX verdict of 'avoid' follows from the company's inability to generate sustainable profits despite revenue growth and a weak balance-sheet safety score. The most critical factor is the zero net profit and poor capital efficiency, which signal a lack of financial health and profitability.
Summarised by DocStoX's model on 2026-09-08 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
This price may be out of date. Last traded ₹8.90 on 9 Oct 2026 (8 days ago). Not a live price.
DocStoX Score
3.4/10
Poor
Fair Value
Sign in to see
ROE
1.12%
Weak
P/E
44.50x
Expensive
Debt / Equity
1.79
High
Industry
Healthcare
Pharmaceuticals
Overall View
Poor
Price performance
52W₹7.50
₹22.05
DocStoX take
Held back by momentum (0.0).
DocStoX score
Low confidence3.4
/10
Poor
Quality
Weak
ROE 1.1%
Valuation
Rich
P/E 44.5×
Growth
Slow
Revenue +35.0% 5Y CAGR
Risk
Moderate
D/E 1.79
Momentum
Weak
10% of 52-week range
At a glance
Market Cap
₹16 Cr
52W High / Low
₹22 / ₹8
Dividend Yield
0.00%
Promoter Holding
56.72%
EPS (TTM)
₹0.20
Book Value
₹17.86
Key highlights
- Revenue compounding 35% a year
- Profitable in all of the last 4 years
- High leverage — debt is 1.8× equity
- Momentum is weak (0.0/10)
2 Positives4 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore Mono Pharmacare Limited’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Mono Pharmacare Limited peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
SUN PHARMACEUTICAL IND LDIVI S LABORATORIES LTDTORRENT PHARMACEUTICALS LAPOLLO HOSPITALS ENTER. LZYDUS LIFESCIENCES LTDLAURUS LABS LIMITEDCIPLA LTDDR. REDDY S LABORATORIESAUROBINDO PHARMA LTDMANKIND PHARMA LIMITEDLUPIN LIMITEDMANIPAL HEALTH ENTERPRI L
Compare Mono Pharmacare Limited with peers
Mono Pharmacare Limited vs SUN PHARMACEUTICAL IND LMono Pharmacare Limited vs DIVI S LABORATORIES LTDMono Pharmacare Limited vs TORRENT PHARMACEUTICALS LMono Pharmacare Limited vs APOLLO HOSPITALS ENTER. LMono Pharmacare Limited vs ZYDUS LIFESCIENCES LTDMono Pharmacare Limited vs LAURUS LABS LIMITED
Related tools & concepts
Value Mono Pharmacare Limited with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing